Akzo Nobel (ENXTAM:AKZA) Stock Faces Q3 Earnings Loss Despite Margin Gains

Akzo Nobel came into this Q3 2026 earnings print with its stock parked around €60.96 and a valuation story framed by a 16x P/E that sat well below many coatings peers. The surprise is that behind a modestly moving share price, the quarter itself delivered a hit to the income statement. Management reported a loss of €177m from ongoing activities and basic earnings per share of €1.04 in the red, even as adjusted EBITDA and margins told a steadier operational story.

Like the operational progress but worried about a headline loss hitting the income statement? Compare Akzo Nobel's setup with a curated group of resilient businesses in our list of solid balance sheet and fundamentals stocks (203 results)

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): €2,538 million vs. €2,547 million (broadly stable top line)
• Net Loss from Ongoing Activities (Q3 2026 vs. Q3 2025): €177 million loss vs. €193 million loss (smaller loss year on year)
• Basic EPS (Q3 2026 vs. Q3 2025): €1.04 loss per share vs. €1.13 loss per share (reduced loss per share)
• Adjusted EBITDA Margin (Q3 2026 vs. prior quarter trend): 15.3% in Q3 2026 with expansion for a sixth consecutive quarter (continued margin improvement on an adjusted basis)

Earnings grab the headlines, but valuation work often starts with the cash flowing through Akzo Nobel and how reliably that stream supports the balance sheet. When cash generation does the talking for Akzo Nobel, the stock could be a whopping 45% undervalued.

Akzo Nobel’s Bull Case Meets Real Execution Milestones

The bullish script argues that Akzo Nobel’s self help on costs will translate into stronger profitability as demand steadies.

"Execution of the SG&A and Industrial Excellence programs, with a combined €0.5b of gross cost takeout and carryover benefits into 2026 and 2027, is set to create meaningful operating leverage as volumes stabilize."

Q3 offers tangible proof on the first half of that sentence. Adjusted EBITDA margin reached 15.3% for a sixth straight quarter of improvement, even with group volumes down 2% and decorative volumes down 3%. Pricing was up 5% and working capital efficiency improved, which together suggest the cost and productivity agenda is already lifting earnings quality, even before any Axalta merger synergies arrive.

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for.

Akzo Nobel Bear Case: Execution Risks Still Visible

The cautious view argues that Akzo Nobel could struggle to turn restructuring headlines into dependable earnings power as projects drag or underdeliver.

"The €500 million cost takeout from SG&A and industrial programs, including 2,900 position reductions and at least €300 million of industrial savings, is designed to create operating leverage on any eventual volume recovery and affect margins and earnings quality."

Q3 adjusted EBITDA margin at 15.3% with volumes down 2% challenges the idea that savings only work with a volume rebound. Yet the reported €177m loss and merger related cash costs show that earnings quality is not clean. That mix keeps bearish concerns about execution and the true net benefit of these programs very much alive.

Hunt Mispriced Earnings Stories Now

Akzo Nobel shows how headline losses can obscure quieter progress in margins and cash discipline. The real opportunity is finding stocks that could be undervalued before the market corrects them.

• Company 1 - 44% below our estimate - uses a high retention banker model to manage a major merger while focusing on credit quality and fee income.
• Company 2 - 32% below our estimate - redirects capital toward higher margin industrial bearings as cost programs release cash and an automotive separation reshapes the portfolio.
• Company 3 - 40% below our estimate - builds a premium teahouse network where a fast growing membership base supports new store openings and higher repeat spending.

Three companies from the same screener. Open the full list of 190 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com